Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use

Table 1 Demographic and clinical characteristics of participants with HIV and opioid use disorder who initiated clinic-based buprenorphine in the Johns Hopkins HIV Clinical Cohort, 2013–2020

	N = 179
Age^a	52.8 (8.04)
Present gender, male	112 (63%)
Race/Ethnicity
Non-Hispanic White	28 (16%)
Non-Hispanic Black	147 (82%)
Hispanic	3 (2%)
Other	1 (1%)
HIV Acquisition Risk Factor^b
Men who have sex with men	16 (9%)
Injection drug use	101 (56%)
Heterosexual sex	122 (68%)
Buprenorphine start year
2013	40 (22%)
2014	25 (14%)
2015	3 (2%)
2016	17 (10%)
2017	19 (11%)
2018	20 (11%)
2019	30 (17%)
2020	25 (14%)
Recent cocaine use	57 (32%)
Missing	17 (10%)
Recent hazardous alcohol use	39 (22%)
Missing	14 (8%)
Died	33 (18%)

^a Mean (SD)
^b HIV acquisition risk factors are not mutually exclusive. Patients could report one or more risk factors

ISSN: 1940-0640